Nemaura Medical announce Professor Osama Hamdy Joins their Advisory Board
September 17 2021 - 9:05AM
Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a
medical technology company focused on developing and
commercializing non-invasive wearable diagnostic devices and
supporting personalized lifestyle coaching programs, announces that
Dr. Osama Hamdy, MD, PhD, has joined their advisory board as
consultant, and is expected to partake on and advise on Key Opinion
leader studies in both the Diabetes field and Metabolic Health
field using Nemaura’s glucose monitoring technology in the near
future.
Dr. Hamdy is a senior endocrinologist and
medical director, Obesity Clinic Program at the Joslin Diabetes
Center and an associate professor of medicine at Harvard Medical
School. Dr. Hamdy is a world renowned thought leader in the field
of obesity management in diabetes, medical nutrition and digital
health. Many of his discoveries and innovations are currently
shaping these fields. His professional work focuses on
understanding metabolic and cardiovascular benefits of lifestyle
changes and weight loss, and he is currently investigating the
cardiovascular benefits of short- and long-term weight reduction in
obese individuals with and without type 2 diabetes.
“We are truly gratified to have a practicing
clinician that has changed the real-world treatment of diabetes
management as an advisor to us for some upcoming KOL studies,” said
Nemaura CEO Dr. Faz Chowdhury. “These studies will allow us to
better impact patient health, and we expect the counsel and input
from Dr. Hamdy to be meaningful in helping us to deliver
non-invasive treatment options to further enrich people’s
lives.”
Dr. Hamdy has translated the successful clinical
research results of two landmark studies in diabetes into a
clinical practice model through the creation of Joslin’s Why WAIT
(Weight Achievement and Intensive Treatment) Program, which serves,
in part, as the basis for Nemaura’s lifestyle program,
BEAT®diabetes.
About Nemaura Medical, Inc.
Nemaura Medical Inc. is a medical technology
company developing and commercializing non-invasive wearable
diagnostic devices. The company is currently commercializing
sugarBEAT® and proBEAT™. sugarBEAT®, a CE mark approved Class IIb
medical device, is a non-invasive and flexible continuous glucose
monitor (CGM) providing actionable insights derived from real time
glucose measurements and daily glucose trend data, which may help
people with diabetes and pre-diabetes to better manage, reverse,
and prevent the onset of diabetes. Nemaura has submitted a PMA
(Premarket Approval Application) for sugarBEAT® to the U.S. FDA.
proBEAT™ combines non-invasive glucose data processed using
artificial intelligence and a digital healthcare subscription
service and has been launched in the U.S. as a general wellness
product as part of its BEAT®diabetes program.
The Company sits at the intersection of the
global Type 2 diabetes market that is expected to reach nearly $59
billion by 2025, the $50+ billion pre-diabetic market, and the
wearable health-tech sector for weight loss and wellness
applications that is estimated to reach $60 billion by 2023.
For more information, please visit www.NemauraMedical.com.
Contact:
Jules AbrahamCORE IR917-885-7378julesa@coreir.com
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Jul 2023 to Jul 2024